How Eli Lilly Is Thinning Out the Competition

How Eli Lilly Is Thinning Out the Competition

Source: 
Motley Fool
snippet: 

Pharmaceutical company Eli Lilly (LLY 2.58%) scored a major approval three months ago with its state-of-the-art diabetes drug, Mounjaro. It is too early to tell whether the drug will boost Lilly's sagging revenue, but it does have enormous potential in several huge markets. Early results suggest that the drug could help the company capture crucial share in these key segments.